Tolerability of Montelukast

Drugs

Volumn 59, Issue SUPPL. 1, 2000, Pages 35-42

  Price, David ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOCHROME; FEXOFENADINE; LEUKOTRIENE; MONTELUKAST; NEDOCROMIL; PHENOBARBITAL; PREDNISOLONE; TERFENADINE; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST;

ASTHMA; CHILD; CHURG STRAUSS SYNDROME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR NOSE THROAT DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; NEUROLOGIC DISEASE; REVIEW; SKIN DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION;

EID: 0034031917     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059001-00006     Document Type: Review

References (24)

1. Cheng H, Leff JA, Amin R, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996; 13: 445-8
2. Singulair prescribing information. Whilehouse Station, NJ, USA: Merck & Co. Inc., June 1999
3. China M, Xu X, Nishime JA, et al. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 1997; 25 (9): 1022-31
4. 1 receptor antagonist, in human plasma and bile. Drug Metabol Dispos 1997; 25: 1282-7
5. Montelukast. In: Olin BR, editor. Drug facts and comparisons. St Louis: Facts and Comparisons, Inc. 1998: 179n-179q
6. Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1999; 39 (5): 495-500
7. Malmstrom K, Schwartz J, Reiss TF, et al. Effect of montelukast on single-dose theophylline pharmacokinetics. Am J Ther 1998; 5 (3): 189-95
8. Knorr B, Matz J, Bernstein A, et al. Montelukast for chronic asthma in 6-to 14-year-old children. A randomised, double-blind trial. JAMA 1998; 279: 1181-6
9. Noonan G, Reiss TF, Shingo S, et al. Montelukast (MK-0476) maintains long-term asthma control in adult and pediatric patients (aged > or equal to 6 years). Am J Respir Crit Care Med 1999; 159: A640
10. Thomson NC. What is the future for inhaled steroids in adult asthma care? Asthma Gen Pract 1998; 6: 32-4
11. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med 1997; 337: 1659-65
12. Verberne AAP, Frost C, Roorda AJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997; 156: 688-95
13. Tinkelman DG, Reed CE, Nelson HS, et al. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993; 92 (1): 64-77
14. Doull IJ, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995; 151 (6): 1715-9
15. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994; 93: 967-76
16. Silverstein MD, Yunginger JW, Reed CE, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol 1997; 99: 466-74
17. Allen DB, Bronsky HA, LaForce CF, et al. Growth in asthmatic children treated with fluticasone propionate. J Pediatr 1998; 132: 472-7
18. Price D, Hobbs J, Watkins S, et al. Concerns and misconceptions regarding steroid therapy in asthma: findings and impact of a public meeting. Asthma Gen Pract 1998; 6: 43-4
19. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130 (6): 487-95
20. Edelman JM, Preston SR, Turpin JA, et al. Parent and child preferences for montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in asthmatic children ages 6 to 11. Eur Resp J 1998; 12 Suppl. 29: 18S
21. Price DB, Wolfe S. Montelukast: clinical and cost effectiveness in primary care. Am J Respir Crit Care Med 1999; 159: A640
22. Wechsler ME, Garpestad E, Flier ER, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279: 455-7
23. MedWatch: The FDA Medical Products Reporting Program. New safely information summaries 1999 [online]. Available from: http://www.fda.gov/medwatch 1999/safety99.him [Accessed 1999 Oct 15]
24. World Health Organization (WHO) Pharmaceuticals Newsletter. WHO, 1998: nos 9 & 10